Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 14/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CBS | P35520 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2435519 | 0.90 | CASR (0.81) | CASRALDH1A1NPC1RAB9A | |
| SCHEMBL2430642 | 0.87 | CASR (1.00) | CASRALDH1A1NPC1RAB9A | |
| SCHEMBL2436352 | 0.87 | CASR (0.77) | CASREPHX2ALDH1A1NPC1RAB9A | |
| SCHEMBL2431155 | 0.87 | CASR (0.77) | CASREPHX2ALDH1A1NPC1RAB9A | |
| SCHEMBL2429151 | 0.87 | CASR (0.76) | CASRALDH1A1NPC1RAB9A | |
| SCHEMBL2437588 | 0.86 | CASR (0.74) | CASREPHX2ALDH1A1RAB9A | |
| SCHEMBL14310626 | 0.85 | CASR (0.74) | CASREPHX2 | |
| SCHEMBL2431141 | 0.85 | CASR (1.00) | CASRALDH1A1 | |
| SCHEMBL2430546 | 0.85 | CASR (0.76) | CASREPHX2 | |
| SCHEMBL12329370 | 0.84 | CASR (0.72) | CASRALDH1A1CBSNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366698-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | Galapagos SAS (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
| WO-2008006625-A2 | DERIVATIVES OF UREA AND RELATED DIAMINES, METHODS FOR THEIR MANUFACTURE, AND USES THEREFOR | GALAPAGOS SAS (FR) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | UTS2R, CASR, GPR17 | CASR 2/4885EPHX2 3399/4885ALDH1A1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.